Kymera Therapeutics to Participate in Upcoming December Investor Conferences
Kymera Therapeutics (NASDAQ: KYMR), a clinical-stage biopharmaceutical company focused on targeted protein degradation, has announced its participation in two major investor conferences this December. The company will engage in fireside chats at the Piper Sandler 36th Annual Healthcare Conference in New York on December 3 at 1:00 p.m. ET, and the 7th Annual Evercore ISI HealthCONx Conference in Coral Gables on December 4 at 4:15 p.m. ET. Live webcasts will be available on Kymera's website under the Investors section, with replays accessible after the events.
Kymera Therapeutics (NASDAQ: KYMR), una società biofarmaceutica in fase clinica focalizzata sulla degradazione mirata delle proteine, ha annunciato la sua partecipazione a due importanti conferenze per investitori questo dicembre. L'azienda parteciperà a conversazioni informali alla 36a Conferenza Annuale sulla Salute di Piper Sandler a New York il 3 dicembre alle 13:00 ET, e alla 7a Conferenza Annuale HealthCONx di Evercore ISI a Coral Gables il 4 dicembre alle 16:15 ET. Saranno disponibili webcast dal vivo sul sito web di Kymera nella sezione Investitori, con riproduzioni accessibili dopo gli eventi.
Kymera Therapeutics (NASDAQ: KYMR), una empresa biofarmacéutica en etapa clínica centrada en la degradación selectiva de proteínas, ha anunciado su participación en dos importantes conferencias para inversionistas este diciembre. La compañía participará en charlas informales en la 36ª Conferencia Anual de Salud de Piper Sandler en Nueva York el 3 de diciembre a la 1:00 p.m. ET, y en la 7ª Conferencia Anual HealthCONx de Evercore ISI en Coral Gables el 4 de diciembre a las 4:15 p.m. ET. Las transmisiones en vivo estarán disponibles en el sitio web de Kymera en la sección de Inversores, con repeticiones accesibles después de los eventos.
Kymera Therapeutics (NASDAQ: KYMR)은 표적 단백질 분해에 집중하는 임상 단계의 생명공학 회사로서, 이번 12월에 두 개의 주요 투자자 회의에 참여한다고 발표했습니다. 이 회사는 12월 3일 오후 1시(ET)에 뉴욕에서 열리는 Piper Sandler 제36차 연례 의료 회의와 12월 4일 오후 4시 15분(ET) 에 코랄 게이블스에서 열리는 Evercore ISI 제7차 연례 HealthCONx 회의에서 대담에 참여합니다. Kymera의 웹사이트 투자자 섹션에서 실시간 웹캐스트를 이용할 수 있으며, 이벤트 후 재생 가능 콘텐츠도 제공됩니다.
Kymera Therapeutics (NASDAQ: KYMR), une entreprise bio-pharmaceutique en phase clinique spécialisée dans la dégradation ciblée des protéines, a annoncé sa participation à deux grandes conférences pour investisseurs ce décembre. L'entreprise participera à des discussions informelles lors de la 36e Conférence Annuelle sur la Santé de Piper Sandler à New York le 3 décembre à 13h00 ET, et à la 7e Conférence Annuelle HealthCONx d'Evercore ISI à Coral Gables le 4 décembre à 16h15 ET. Les webcasts en direct seront disponibles sur le site de Kymera dans la section Investisseurs, avec des rediffusions accessibles après les événements.
Kymera Therapeutics (NASDAQ: KYMR), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf gezielte Proteinabbau spezialisiert hat, hat seine Teilnahme an zwei wichtigen Investorenkonferenzen im Dezember bekannt gegeben. Das Unternehmen wird am 3. Dezember um 13:00 Uhr ET an Piper Sandler 36. jährliche Gesundheitskonferenz in New York teilnehmen und am 4. Dezember um 16:15 Uhr ET an der 7. jährlichen Evercore ISI HealthCONx-Konferenz in Coral Gables teilnehmen. Live-Webcasts werden auf der Website von Kymera im Bereich Investoren verfügbar sein, mit Wiederholungen, die nach den Veranstaltungen zugänglich sind.
- None.
- None.
WATERTOWN, Mass., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that the Company will participate in fireside chats at the following upcoming investor events:
- Piper Sandler 36th Annual Healthcare Conference in New York, NY on December 3 at 1:00 p.m. ET; and
- 7th Annual Evercore ISI HealthCONx Conference in Coral Gables, FL on December 4 at 4:15 p.m. ET.
Live webcasts of the presentations will be available under “News and Events” in the Investors section of the Company’s website at www.kymeratx.com. Replays of the webcasts will be archived and available following the events.
About Kymera Therapeutics
Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients’ lives. Kymera is deploying TPD to address disease targets and pathways inaccessible with conventional therapeutics. Having advanced the first degrader into the clinic for immunological diseases, Kymera is focused on building an industry-leading pipeline of oral small molecule degraders to provide a new generation of convenient, highly effective therapies for patients with these conditions. Founded in 2016, Kymera has been recognized as one of Boston’s top workplaces for the past several years. For more information about our science, pipeline and people, please visit www.kymeratx.com or follow us on X or LinkedIn.
| Investor and Media Contact: Justine Koenigsberg Vice President, Investor Relations investors@kymeratx.com media@kymeratx.com 857-285-5300 |
FAQ
When is Kymera Therapeutics (KYMR) presenting at the Piper Sandler Healthcare Conference?
Where can I watch Kymera Therapeutics' (KYMR) December 2024 investor conference presentations?
What investor conferences is Kymera Therapeutics (KYMR) attending in December 2024?
